UK-headquartered, Nasdaq-listed Silence Therapeutics, a clinical-stage biotech company developing short interfering RNA (siRNA) therapies, is raising approximately US$150m through the issue of an underwritten ADS offering. Underwriters have 30-day option to purchase up to an additional 15% of the total number of ADSs. All of the ADSs are being offered by Silence.
Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-runners.
Silence Therapeutics recently announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera (PV).
It has also recently reported a net loss for the three months ended 30 June of US$12.3m versus a net loss of US$27.4m for the three months ended 30 June 2025.
Silence shares are quoted at US$15.43.
